[go: up one dir, main page]

WO1997034564A2 - Traitement des maladies inflammatoires chroniques de l'intestin par une association de plantes - Google Patents

Traitement des maladies inflammatoires chroniques de l'intestin par une association de plantes Download PDF

Info

Publication number
WO1997034564A2
WO1997034564A2 PCT/DE1997/000481 DE9700481W WO9734564A2 WO 1997034564 A2 WO1997034564 A2 WO 1997034564A2 DE 9700481 W DE9700481 W DE 9700481W WO 9734564 A2 WO9734564 A2 WO 9734564A2
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
crohn
wormwood
resin
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1997/000481
Other languages
German (de)
English (en)
Other versions
WO1997034564A3 (fr
Inventor
L. M. Osama Omer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO1997034564A2 publication Critical patent/WO1997034564A2/fr
Publication of WO1997034564A3 publication Critical patent/WO1997034564A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9064—Amomum, e.g. round cardamom

Definitions

  • Chronic inflammatory immune diseases of the intestine include ulcerative colitis, Crohn's disease, which is also known as granulomatous colitis, and in a broader sense colon irretables and diverticulitis. They are also summarized under the term "unspecific inflammatory bowel diseases". The causes of these diseases are made up of partly known, partly still unclear factors. Coltis granulomatosa (Crohn's disease) and ulcerative colitis are clinically related and sometimes (approx. 10%) occur together. Numerous immune reactions occur in the intestinal area, which are primarily to be understood as a protective function of the immune system. Clinical and immunological findings suggest that the incorrect control of the immune reactions is causally or reactively involved in the development and course of these chronic inflammatory bowel diseases.
  • Corticoids, salicyl azosulfapyridme (azulfidines) and immunosuppressants such as azathiopnn are available for the treatment of these diseases. Since these diseases run in episodes and tend to relapse, which are often not predictable, the aim of the therapy should be to treat the individual episode as quickly as possible (within a week) and as free of side effects as possible. Long-term remission and improvement in general well-being had to be the goal. Corticoids undoubtedly act quickly in the acute phase, but are hardly suitable for long-term therapy. The side effects of long-term corticoid therapy are full of dangers and often unacceptable. The azulfidines act significantly slower than corticoid therapy.
  • Effective phytopharmaceuticals are synthetic because of the lack of side effects. table medicines are preferable. Apart from opium, no phytotherapy is available for the treatment of chronic inflammatory bowel diseases.
  • the invention has set itself the task of creating a risk-free, rapid onset and long-lasting phytotherapeutic alternative for chronic inflammatory bowel diseases. This task was accomplished with the following plants and their combinations: wormwood (artemesia absinthium vulgaris) mastic resin (resin pistacia lenticus) cardamom fruit (fructus elettaria cardamomum)
  • the above Plants or their parts are known drugs. Their use in unspecific inflammation of the intestine such as Crohn's disease, ulcerative colitis, diverticulitis and irritable bowel is not known.
  • the invention describes the anti-inflammatory effect of wormwood, mastic resin, cardamom fruit and rose petals individually and in combination with one another.
  • the individual plants - wormwood, mastic resin, rose petals and cardamom fruit were found to have poor anti-Crohn activity. However, they develop in combination with one another, especially when wormwood herb is part of this combination, 90 a clear, clinically useful effect.
  • the mixtures of groups 6 and 7 were found to be particularly balanced and optimized for the treatment of Crohn's disease. Groups 8, 9 and 10 and groups 1 to 3 were weak in their effect.
  • the individual, independently dried, ground to fine powder and sieved starting materials were mixed together to obtain the According to the invention to give A.
  • the fine powder was filled into size 0 capsules in which the weight of the mixture of 325 mg per capsule was obtained.
  • histology in histological biopsy specimens a diffuse, inflammatory infiltration of the intestinal wall, which consist of lymphocytes, plasma cells and eosinophilic granulocytes, which are typically the
  • Ulcerative colitis like Crohn's disease, is one of the chronic non-specific intestinal inflammations of unknown cause. It primarily affects the mucosa and rarely covers deeper wall layers. It is typical
  • the trial was designed as an open study according to the guidelines of the 195 Declaration of Helsinki and Good Clinical Practice (GCP). All patients gave their consent after the information. The treatment with the mixture according to the invention was continued for 14 days. If there was no improvement in stool quality on day 14, the patients were discharged from the study.
  • GCP Good Clinical Practice

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des plantes médicinales permettant de traiter les inflammations non spécifiques de l'intestin, notamment la maladie de Crohn et la rectocolite hémorragique. L'absinthe (Artemisia absinthium) et/ou les fruits de la cardamome (Elettaria cardamomum fructus) et/ou les roses (Rosae flores) et/ou la résine de lentisque (Pistacia lenticus resin), en poudre ou sous forme d'extraits, possèdent l'action thérapeutique souhaitée.
PCT/DE1997/000481 1996-03-21 1997-03-12 Traitement des maladies inflammatoires chroniques de l'intestin par une association de plantes Ceased WO1997034564A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19611078.5 1996-03-21
DE1996111078 DE19611078C2 (de) 1996-03-21 1996-03-21 Therapie von chronischen entzündlichen Darmerkrankungen mit einer Phytokombination

Publications (2)

Publication Number Publication Date
WO1997034564A2 true WO1997034564A2 (fr) 1997-09-25
WO1997034564A3 WO1997034564A3 (fr) 1998-03-26

Family

ID=7788929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1997/000481 Ceased WO1997034564A2 (fr) 1996-03-21 1997-03-12 Traitement des maladies inflammatoires chroniques de l'intestin par une association de plantes

Country Status (2)

Country Link
DE (1) DE19611078C2 (fr)
WO (1) WO1997034564A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0909563A1 (fr) * 1997-10-17 1999-04-21 OMER, Osama L. M., Dr.Dr. Thérapie d'affections intestinales inflammatoires chroniques à l'aide d'une combinaison de plantes

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2768621B1 (fr) * 1997-09-22 2000-04-07 Oreal Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees
EP1958641A1 (fr) * 2007-02-16 2008-08-20 Bionature E.A. Limited Traitement et prévention de l'inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3820218A1 (de) * 1988-06-14 1989-12-28 Osama L M Dr Med Dr Rer N Omer Phytotherapeutikum zur behandlung von depressivem syndrom
DE69331727D1 (de) * 1992-06-30 2002-04-25 Howard K Shapiro Verwendung einer kombination bestehend aus einem aminderivat oder aminverwandten derivat der benzoesäure und einem amino-polysaccharide zur herstellung eines medikaments fuer die behandlung von entzündlichen erkrankungen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0909563A1 (fr) * 1997-10-17 1999-04-21 OMER, Osama L. M., Dr.Dr. Thérapie d'affections intestinales inflammatoires chroniques à l'aide d'une combinaison de plantes

Also Published As

Publication number Publication date
WO1997034564A3 (fr) 1998-03-26
DE19611078A1 (de) 1996-09-19
DE19611078C2 (de) 1997-10-02

Similar Documents

Publication Publication Date Title
DE3046559C2 (fr)
DE69720985T2 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
DE69822822T2 (de) Verwendung einer Zusammensetzung enthaltend Capsaicin oder Resiniferatoxin zur Behandlung des Reizdarmsyndroms
EP2274315B1 (fr) Compositions comprenant du galactomannane et leur procédé de fabrication
EP1107775A1 (fr) Composition contenant des petasites exempts de pyrrolizidinalcaloides
EP0125634B1 (fr) Utilisation d'une substance sécrétolytique pour l'obtention d'un agent contre le ronflement et pour combattre le phénomène de ronflement
US8288364B2 (en) Botanically derived composition and a process thereof
WO2009036906A1 (fr) Composition avec combinaison de principes actifs constituée d'un laxatif et d'un agent antimoussant, pour le traitement de la constipation
DE69824619T2 (de) Verfahren zur vorbeugung von durch zyklosporine oder tacrolimus verursachter nierenvergiftung
Sundberg et al. Evaluation of lipoid pneumonia
EP2858655B1 (fr) Extraits de serpolet et leur utilisation
DE19611078C2 (de) Therapie von chronischen entzündlichen Darmerkrankungen mit einer Phytokombination
WO1999051250A1 (fr) Utilisation d'extraits d'echinacea pallida et d'echinacea angustifolia; extraits de dents de lion (taraxacum); extraits de plantain (plantago)
Maksimović On Frankincense
DE3152319T1 (fr)
EP0909563A1 (fr) Thérapie d'affections intestinales inflammatoires chroniques à l'aide d'une combinaison de plantes
EP0256353A2 (fr) Traitement pharmaceutique contre une mauvaise absorption d'aliments ou de médicaments oraux
EP1941891B1 (fr) Preparation destinee a traiter des maladies intestinales inflammatoires non infectieuses
EP0002803B1 (fr) Cis triméthyl-3,3,5 cyclohexanol utilisable dans le traitement des maladies bilieuses
DE60216979T2 (de) Synergistische hepatoprotektive Zusammensetzung aus trans-Tetracos-15-ensäure und Apocynin und Verwendung davon
EP3883557A1 (fr) Composition destinée à être utilisée dans la prévention et/ou le traitement symptomatique du syndrome du côlon irritable
DE3317558A1 (de) Orales antischnarchmittel
DE60217720T2 (de) Kurkumin-zusammensetzung zur heilung von dickdarmpolypen
WO2023242339A1 (fr) Composition comprenant de la pétasine et de l'isopétasine ayant un effet hépatoprotecteur
CN117224590A (zh) 一种用于心脑血管疾病的中药组合物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase